Ratings PTC Therapeutics, Inc.

Equities

PTCT

US69366J2006

Market Closed - Nasdaq Other stock markets 01:30:00 30/04/2024 am IST			5-day change	1st Jan Change
32.14 ^USD	+12.50%		+23.76%	+16.62%

12:18pm	North American Morning Briefing : More Earnings -2-	DJ
29/04	Morgan Stanley Upgrades PTC Therapeutics to Equalweight From Underweight, Adjusts PT to $30 From $28	MT

Summary

Overall, the company has poor fundamentals for a medium to long-term investment strategy.
From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Strengths

The company is in a robust financial situation considering its net cash and margin position.

Weaknesses

As estimated by analysts, this group is among those businesses with the lowest growth prospects.
As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
Low profitability weakens the company.
With an enterprise value anticipated at 2.99 times the sales for the current fiscal year, the company turns out to be overvalued.
For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
The three month average target prices set by analysts do not offer high potential in comparison with the current prices.
Over the past twelve months, analysts' consensus has been significantly revised downwards.
Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
The company's earnings releases usually do not meet expectations.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
PTC THERAPEUTICS, INC.	+16.62%	2.47B	B
VERTEX PHARMACEUTICALS INCORPORATED	-2.63%	102B	B+
REGENERON PHARMACEUTICALS, INC.	+1.62%	96.29B	B+
ARGENX SE	+2.62%	22.18B	B
BIONTECH SE	-16.67%	21.2B	B+
GENMAB A/S	-8.84%	18.31B	A-
WUXI APPTEC CO., LTD.	-38.74%	17.38B	A-
BEIGENE, LTD.	-13.21%	16.36B	B
NEUROCRINE BIOSCIENCES, INC.	+5.41%	13.97B	C+
SAREPTA THERAPEUTICS, INC.	+33.57%	12.17B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes